NRSN
Neurosense Therapeutics LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$25.38M
P/E Ratio
—
EPS
$-0.44
Beta
1.68
52W High
$2.60
52W Low
$0.63
50-Day MA
$0.87
200-Day MA
$1.18
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Neurosense Therapeutics Ltd
Neurosense Therapeutics Ltd (NRSN) is a clinical-stage biotechnology firm focused on developing groundbreaking therapies for neurodegenerative diseases, with a primary emphasis on Parkinson's disease. Through its proprietary development platform, the company is actively advancing several therapeutic candidates in critical clinical trials, highlighting its dedication to addressing significant unmet needs in neurology. Led by an experienced management team and supported by strategic partnerships, Neurosense is well-positioned to provide innovative treatment solutions that enhance patient quality of life while establishing a strong foothold in the biopharmaceutical industry.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-11.07M |
| Operating Margin | 0.00% |
| Return on Equity | -2175.00% |
| Return on Assets | -247.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.05 |
| Price-to-Book | 12.82 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -1.16 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $33.40M |
| Float | $26.21M |
| % Insiders | 18.66% |
| % Institutions | 0.98% |
Analyst Ratings
Consensus ($8.38 target)
4
BuyData last updated: 4/9/2026